Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 208

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 208
---

    By:
    /s/ James Rolke

    Chief Executive Officer and Director

     Date:  March 6, 2025
    By:
    /s/ George F.Tidmarsh, MD, PhD

    Chairman and Director

      Date:  March 6, 2025
    By:
    /s/ Chester S. Zygmont, III

    Chief Financial Officer and Principal Accounting Officer

      Date:  March 6, 2025
    By:
    /s/ Jennifer Carver

    Director

      Date:  March 6, 2025
    By:
    /s/ Jess Roper

    Director

      Date:  March 6, 2025
    By:
    /s/ Lakhmir Chawla, MD

    Director

 87

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

REVELATION BIOSCIENCES, INC.

    Report of Independent Registered Public Accounting Firm (PCAOB ID 23)
     
    F-2

    Consolidated Balance Sheets
     
    F-4

    Consolidated Statements of Operations
     
    F-5

    Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
     
    F-6

    Consolidated Statements of Cash Flows
     
    F-7

    Consolidated Notes to the Financial Statements
     
    F-8 – F-28

 F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Revelation Biosciences, Inc.

Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Revelation Biosciences, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders' equity (deficit), and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America